Leramistat

First in a pipeline of new programmed disease-resolving drugs.

The progression of rheumatoid arthritis reflects a cycle of inflammation, damage and disability. Whilst inflammation is well-accepted to drive progressive bone damage, the by-products of cartilage and bone damage are themselves inflammatory. This sets up a vicious cycle of autoimmune destruction which leads to progressive disability. The existing treatments, the “disease-modifying antirheumatic drugs” (DMARDs) are very effective in suppressing joint inflammation. However, they also shift bone dynamics to prevent repair of structural damage.

Leramistat is an oral treatment that selectively modulates inflammation at the level of tissue damage, adapting to stimulus strength. By avoiding outright inhibition of inflammatory cytokine cascades and promoting a pro-repair environment, leramistat fine-tunes control of subclinical inflammation and restores normal bone dynamics to resolve rheumatoid pathology at its source. With its unique “pro-repair” mechanism, leramistat offers a new foundational option for combination therapy, enabling other disease-modifying treatments to work better for longer and elevating the definition of remission.

Leramistat is currently in clinical development for the treatment of patients with moderate to severe rheumatoid arthritis who have not had a satisfactory response to their initial DMARD therapy.